Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milsaperidone adjunctive therapy for major depressive disorder
2024-520333-68-00Phase 3Authorised
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Milsaperidone adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS). Planned start Sep 2025; status: authorised.
02
Drugs
milsaperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-520333-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520333-68-00.